142 filings
8-K
MRTX
Mirati Therapeutics Inc
23 Jan 24
Contingent Value Rights Agreement
8:48am
8-K
MRTX
Mirati Therapeutics Inc
19 Dec 23
Other Events
7:30am
8-K
MRTX
Mirati Therapeutics Inc
13 Dec 23
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
MRTX
Mirati Therapeutics Inc
24 Nov 23
Other Events
4:45pm
8-K
MRTX
Mirati Therapeutics Inc
13 Nov 23
Other Events
12:00am
8-K
ef3t62xqj 3gf2e
6 Nov 23
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
8:05am
8-K
a7q0gr3 l1
10 Oct 23
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
7:33am
8-K
0kuqopted4cthvv qip
23 Aug 23
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
4:01pm
8-K
dtlg qlypwp8e3ld3io
9 Aug 23
Mirati Therapeutics Announces Proposed Public Offering
4:40pm
8-K
sg11s33vdpgsb0euz
8 Aug 23
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
4:01pm
8-K
4u5s 4mfbrxhd
21 Jul 23
Other Events
6:05am
8-K
7k978opv
23 Jun 23
Departure of Directors or Certain Officers
4:02pm
8-K
vcqb8 ptq5xnlh
24 May 23
Other Events
4:09pm
8-K
ougbahp5ciq wn2275x
12 May 23
Departure of Directors or Certain Officers
4:02pm
8-K
gy2vkw
9 May 23
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
4:06pm
8-K
pkamrlb6l34t1h78eu
28 Feb 23
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
4:08pm
8-K
34eqwk1mhuq tpbocf
9 Jan 23
Results of Operations and Financial Condition
1:06pm
8-K
htyy bkr7
12 Dec 22
Other Events
8:22pm
8-K
t8y smppa41v
5 Dec 22
Other Events
7:00pm
8-K
nrkrhr
2 Dec 22
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
8:01am